Sirtuin‐3 (SIRT3), a novel potential therapeutic target for oral cancer

Abstract

BACKGROUND: Several sirtuin family members (SIRT1‐7), which are evolutionarily conserved NAD‐dependent deacetylases, play an important role in carcinogenesis. However, their role in oral cancer has not yet been investigated. Therefore, the objective of this study was to investigate whether sirtuins play a role in oral cancer carcinogenesis. METHODS: The expression levels of all sirtuins in several oral squamous cell carcinoma (OSCC) cell lines were compared with normal human oral keratinocytes and observed that SIRT3 was highly expressed. Therefore, tissue microarrays were used to evaluate the clinical relevance of this overexpression. SIRT3 down‐regulation in OSCC cell proliferation and survival was investigated and analyzed by using cell‐proliferation and cell‐viability assays. Ionizing radiation and cisplatin were used to investigate whether SIRT3 down‐regulation could increase the sensitivity of OSCC to both treatments. To further assess the in vivo role of SIRT3 in OSCC carcinogenesis, a floor‐of‐mouth oral cancer murine model was used to study the effect of SIRT3 down‐regulation on OSCC tumor growth in immunodeficient mice. RESULTS: The current results demonstrated for the first time that SIRT3 is overexpressed in OSCC in vitro and in vivo compared with other sirtuins. Down‐regulation of SIRT3 inhibited OSCC cell growth and proliferation and increased OSCC cell sensitivity to radiation and cisplatin treatments in vitro. SIRT3 down‐regulation also reduced tumor burden in vivo. CONCLUSIONS: The current investigation revealed a novel role for SIRT3 in oral cancer carcinogenesis as a promoter of cell proliferation and survival, thus implicating SIRT3 as a new potential therapeutic target to treat oral cancer. Cancer 2011. © 2010 American Cancer Society.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 40

1. 1.

   Bsoul SA, Huber MA, Terezhalmy GT. Squamous cell carcinoma of the oral tissues: a comprehensive review for oral healthcare providers. J Contemp Dent Pract. 2005;6:1-16.

   Not in our library

2. 2.

   Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Fact Sheets: Oral Cavity and Pharynx. 2009.

   Not in our library

3. 3.

   Taylor DM, Maxwell MM, Luthi-Carter R, Kazantsev AG. Biological and potential therapeutic roles of sirtuin deacetylases. Cell Mol Life Sci. 2008;65:4000-4018.

   Not in our library10.1007/s00018-008-8357-y

4. 4.

   Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007;26:5489-5504.

   Not in our library10.1038/sj.onc.1210616

5. 5.

   Haigis MC, Guarente LP. Mammalian sirtuins—emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006;20:2913-2921.

   Not in our library10.1101/gad.1467506

6. 6.

   Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303:2011-2015.

   Not in our library10.1126/science.1094637

7. 7.

   Fu M, Liu M, Sauve AA, et al. Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol. 2006;26:8122-8135.

   Not in our library10.1128/mcb.00289-06

8. 8.

   Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008;14:312-323.

   Not in our library10.1016/j.ccr.2008.09.001

9. 9.

   Bellizzi D, Dato S, Cavalcante P, et al. Characterization of a bidirectional promoter shared between 2 human genes related to aging: SIRT3 and PSMD13. Genomics. 2007;89:143-150.

   Not in our library10.1016/j.ygeno.2006.09.004

10. 10.

    Bellizzi D, Rose G, Cavalcante P, et al. A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics. 2005;85:258-263.

    Not in our library10.1016/j.ygeno.2004.11.003

11. 11.

    Rose G, Dato S, Altomare K, et al. Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Exp Gerontol. 2003;38:1065-1070.

    Not in our library10.1016/s0531-5565(03)00209-2

12. 12.

    Cooper HM, Spelbrink JN. The human SIRT3 protein deacetylase is exclusively mitochondrial. Biochem J. 2008;411:279-285.

    Not in our library10.1042/bj20071624

13. 13.

    Schwer B, North BJ, Frye RA, Ott M, Verdin E. The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol. 2002;158:647-657.

    Not in our library10.1083/jcb.200205057

14. 14.

    Chen XJ, Clark-Walker GD. Sir2 mutants of Kluyveromyces lactis are hypersensitive to DNA-targeting drugs. Mol Cell Biol. 1994;14:4501-4508.

    Not in our library10.1128/mcb.14.7.4501-4508.1994

15. 15.

    Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell. 2005;16:4623-4635.

    Not in our library10.1091/mbc.e05-01-0033

16. 16.

    Shi T, Wang F, Stieren E, Tong Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem. 2005;280:13560-13567.

    Not in our library10.1074/jbc.m414670200

17. 17.

    Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci U S A. 2002;99:13653-13658.

    Not in our library10.1073/pnas.222538099

18. 18.

    Lombard DB, Alt FW, Cheng HL, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol. 2007;27:8807-8814.

    Not in our library10.1128/mcb.01636-07

19. 19.
    Altered sirtuin expression is associated with node-positive breast cancer · 2006

    No notice
20. 20.

    Sundaresan NR, Samant SA, Pillai VB, Rajamohan SB, Gupta MP. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol. 2008;28:6384-6401.

    Not in our library10.1128/mcb.00426-08

21. 21.

    Yang H, Yang T, Baur JA, et al. Nutrient-sensitive mitochondrial NAD(+) levels dictate cell survival. Cell. 2007;130:1095-1107.

    Not in our library10.1016/j.cell.2007.07.035

22. 22.
    p53-Induced Growth Arrest Is Regulated by the Mitochondrial SirT3 Deacetylase · 2010

    No notice
23. 23.

    Henson B, Li F, Coatney DD, et al. An orthotopic floor-of-mouth model for locoregional growth and spread of human squamous cell carcinoma. J Oral Pathol Med. 2007;36:363-370.

    Not in our library10.1111/j.1600-0714.2007.00549.x

24. 24.

    Ota H, Tokunaga E, Chang K, et al. Sirt1 inhibitor, sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene. 2006;25:176-185.

    Not in our library10.1038/sj.onc.1209049

25. 25.

    Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001;107:137-148.

    Not in our library10.1016/s0092-8674(01)00524-4

26. 26.

    Bauer JA, Trask DK, Kumar B, et al. Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther. 2005;4:1096-1104.

    Not in our library10.1158/1535-7163.mct-05-0081

27. 27.

    Wolter KG, Wang SJ, Henson BS, et al. (−)-Gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia. 2006;8:163-172.

    Not in our library10.1593/neo.05691

28. 28.

    Marfe G, Tafani M, Indelicato M, et al. Kaempferol induces apoptosis in 2 different cell lines via Akt inactivation, Bax and SIRT3 activation, and mitochondrial dysfunction. J Cell Biochem. 2009;106:643-650.

    Not in our library10.1002/jcb.22044

29. 29.

    Allison SJ, Milner J. SIRT3 is pro-apoptotic and participates in distinct basal apoptotic pathways. Cell Cycle. 2007;6:2669-2677.

    Not in our library10.4161/cc.6.21.4866

30. 30.

    Schild D. Suppression of a new allele of the yeast RAD52 gene by overexpression of RAD51, mutations in srs2 and ccr4, or mating-type heterozygosity. Genetics. 1995;140:115-127.

    Not in our library10.1093/genetics/140.1.115

31. 31.

    Benigni A, Corna D, Zoja C, et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest. 2009;119:524-530.

    Not in our library10.1172/jci36703

32. 32.

    Scher MB, Vaquero A, Reinberg D. SirT3 is a nuclear NAD+-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev. 2007;21:920-928.

    Not in our library10.1101/gad.1527307

33. 33.

    Nakamura Y, Ogura M, Tanaka D, Inagaki N. Localization of mouse mitochondrial SIRT proteins: shift of SIRT3 to nucleus by co-expression with SIRT5. Biochem Biophys Res Commun. 2008;366:174-179.

    Not in our library10.1016/j.bbrc.2007.11.122

34. 34.

    Stunkel W, Peh BK, Tan YC, et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J. 2007;2:1360-1368.

    Not in our library10.1002/biot.200700087

35. 35.

    Pillai VB, Sundaresan NR, Kim G, et al. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J Biol Chem. 2010;285:3133-3144.

    Not in our library10.1074/jbc.m109.077271

36. 36.

    Kim HS, Patel K, Muldoon-Jacobs K, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell. 2010;17:41-52.

    Not in our library10.1016/j.ccr.2009.11.023

37. 37.

    Grenman R, Burk D, Virolainen E, Wagner JG, Lichter AS, Carey TE. Radiosensitivity of head and neck cancer cells in vitro. A 96-well plate clonogenic cell assay for squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1988;114:427-431.

    Not in our library10.1001/archotol.1988.01860160071024

38. 38.

    Carey TE, Van Dyke DL, Worsham MJ, et al. Characterization of human laryngeal primary and metastatic squamous cell carcinoma cell lines UM-SCC-17A and UM-SCC-17B. Cancer Res. 1989;49:6098-6107.

    Not in our library

39. 39.

    Sequeira J, Boily G, Bazinet S, et al. SIRT1-null mice develop an autoimmune-like condition. Exp Cell Res. 2008;314:3069-3074.

    Not in our library10.1016/j.yexcr.2008.07.011

40. 40.

    Lombard DB, Schwer B, Alt FW, Mostoslavsky R. SIRT6 in DNA repair, metabolism and ageing. J Intern Med. 2008;263:128-141.

    Not in our library10.1111/j.1365-2796.2007.01902.x

Cited by papers we hold 10

• Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells · 2020
  Not checked
• Sirtuins and their Biological Relevance in Aging and Age-Related Diseases · 2020
  No notice
• Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice · 2017
  No notice
• SIRT3: Oncogene and Tumor Suppressor in Cancer · 2017
  No notice
• Insights into the Dichotomous Regulation of SOD2 in Cancer · 2017
  No notice
• Function of the SIRT 3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease · 2016
  No notice
• Sirtuins in metabolism, DNA repair and cancer · 2016
  No notice
• Nisin ZP, a Bacteriocin and Food Preservative, Inhibits Head and Neck Cancer Tumorigenesis and Prolongs Survival · 2015
  No notice
• Functional Annotation Analytics of Genomes Reveals Stress Responsive Acetate Utilization and Sulfate Uptake in the Biotechnologically Relevant · 2012
  Not checked
• Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC 1 · 2012
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.